Provenge® (sipuleucel-T)

Starts the Fight and Helps His
Immune System Sustain* It

PROVENGE is immunotherapy for asymptomatic
or minimally symptomatic metastatic castrate
resistant prostate cancer (mCRPC)

Learn More >

At the time of
metastatic diagnosis

of CRPC patients may be eligible

Treat Early - make sure your patients
take advantage of the PROVENGE window

Learn More >
  • Enrollment
  • Benefit
  • Treatment
  • Apheresis
  • Infusion
  • Billing &

Dendreon ON Call – Supporting Your Practice and Your Patients

Personalized Support For Your PROVENGE Patients
Is Just A Call Away...We Have You Covered

Learn More >

Sustained Immune Response And Short Duration Of Treatment*

Learn More >

Dendreon uses cookies to analyze traffic, enhance your experience, and provide you with tailored content. By continuing to use this site, you agree with our use of cookies and our Privacy Policy. For more information or to opt-out of sale, visit our Privacy Policy.